We assessed the therapeutic applications of WJ-MSCs and AgRP in neurodegenerative diseases by delivering either WJ-MSCs or AgRP directly into the left hippocampus of 10 to 13-month(mo)-old 5XFAD transgenic AD mice. Here, AGRP is linked to Alzheimer disease.